Algorand Foundation Announces Research Leadership
The Algorand Foundation today announced the appointment of Dr. Tal Rabin as the head of research. Named on Forbes World Top 50 Women in Tech 2018 and a member of the National Academy of Arts and Sciences, Dr. Tal Rabin has spent decades pioneering research on cryptographic theory. Dr. Rabin will bring her wealth of experience, specifically around multiparty computations and the design of efficient and provably secure cryptographic protocols, to her work at the foundation.
With core beliefs in the establishment of an open, public and permissionless blockchain, the Algorand Foundation has a vision for an inclusive ecosystem that provides an opportunity for everyone to harness the potential of an equitable and truly borderless economy. With the appointment of Dr. Tal Rabin as the head of research, the foundation is poised to make that vision a reality with broad participation and a focus on cutting-edge research and innovation.
A first-of-its-kind permissionless, pure proof-of-stake blockchain, the Algorand protocol was designed by MIT professor, cryptography pioneer and Turing Award-winner Silvio Micali to support the scale, open participation, and transaction finality needed by users to build opportunity and fulfill the promise of blockchain technology. The Algorand Foundation directs its global efforts from Singapore and is focused on building technology and community around decentralized networks. The foundation, along with the Algorand community, will help launch the Algorand blockchain network while also assisting with research efforts, collaborative roadmap development, and continued growth of the global community.
“Given Dr. Rabin’s experience and academic accomplishments, the Algorand Foundation will be able to take a leadership role in research related to fair access, social justice for all, as well as zero knowledge and secure computation,” said Silvio Micali, founder of Algorand, Inc. “Tal brings tremendous energy to these issues, and I have always admired her passion for philanthropic efforts enabled by technology and innovation, particularly when it comes to her unwavering commitment to gender equality. I am thrilled she has agreed to join the Algorand community.”
“I’ve always believed in the concept of making our world a fairer place, and I trust the Algorand blockchain can create the economic opportunity needed to make that world a reality,” said Rabin. “Our work at the Algorand Foundation will ensure that equitable access to opportunity through decentralized technologies exists, transactions flow freely and everyone has control over their data. I’m excited to start working toward that goal with the accomplished team at the Algorand Foundation.”
In the coming weeks, the Algorand Foundation will share more details about the public network, including the distribution of Algos – the official native token of the Algorand protocol – as well as information about grants for research and development, growth, and economic guidance.
About Algorand Foundation
The Algorand Foundation is providing the trusted infrastructure needed to support the growth of the borderless economy. With research led by Dr. Tal Rabin, a 2018 Forbes World Top 50 Women in Tech, the Algorand Foundation is incorporated in the Republic of Singapore.
For more information, visit https://algorand.foundation.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZOOM International to Begin Doing Business As Elevēo2.6.2020 16:00:00 CEST | Press release
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/ For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry. Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and in
Dr Evidence (DRE), an AI-Enabled SaaS Healthcare Insights Company, Taps Industry Experts Joseph A. Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its Newly Formed Medical Strategy Advisory Board2.6.2020 16:00:00 CEST | Press release
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes. Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts fro
Andersen Global Expands Presence in Qatar2.6.2020 15:30:00 CEST | Press release
Andersen Global announced its collaboration with Doha-based tax firm MS Partner, adding depth to the organization’s presence in Qatar and expanding its global platform. MS Partner was founded in 2018 and includes two Partners and more than 10 professionals that specialize in providing tax services to a variety of international clients including individuals and companies – both private and public. MS Partner’s Chairman His Excellency Shaikh Sultan Bin Jassim Bin Mohammed Al Thani is a prominent business leader in the State of Qatar. “We value our clients and people, and maintain the highest of professional standards,” said Office Managing Director Manikandan Rajan. “We’ve watched Andersen Global grow regionally as well as globally, and the organization has set the standard for providing clients with best-in-class service in an independent and seamless manner. We look forward to working closely with our fellow collaborating firm in Doha, Al-Khalifa Law, as well as all the collaborating f
Pegasus Development AG: Pegasus Present Its New Brand Pegastril - Nuevo2.6.2020 15:06:00 CEST | Press release
The coronavirus pandemic harbours the potential for enormous growth in specific industries. To that end, however, it's important to identify which markets will be dominant in the future. One of the key growth sectors is the production and distribution of disinfectants and associated technologies. Regardless of whether a cure for, or vaccine against, COVID-19 is developed, protection against viruses and bacteria has become incredibly important across the globe and will continue to be a concern going forward. This was one of the reasons why Pegasus Development AG decided to partner with the British disinfectant manufacturer Nuevo. One of the decisive factors choosing Nuevo was its highly competitive product, which is free from alcohol, animal products, perfume, essential oils or dyes. Furthermore, the product has already been tested according to the highest stipulations of the European standard EN 1276, is manufactured according to the latest regulations of the European Biocides Directiv
PVH Corp. Announces Leadership Update at Tommy Hilfiger and PVH Europe2.6.2020 15:00:00 CEST | Press release
PVH Corp. (NYSE:PVH), owner of a portfolio of iconic brands including TOMMY HILFIGER and CALVIN KLEIN, announced today that Daniel Grieder is stepping down from his role of Chief Executive Officer, Tommy Hilfiger Global & PVH Europe after 23 years in various management roles within the organization, and will be leaving the company to pursue other interests. Martijn Hagman will succeed Grieder and become the new Chief Executive Officer, Tommy Hilfiger Global & PVH Europe, effective June 2, 2020. Hagman is currently Chief Operating Officer, Tommy Hilfiger Global & PVH Europe and Chief Financial Officer, Tommy Hilfiger Global, overseeing operations, finance, digital business transformation, technology, business development and the Tommy Hilfiger global sustainability program. He is a 12-year veteran of the Tommy Hilfiger leadership team and has been instrumental in Tommy Hilfiger’s impressive global expansion and the strategy that has led to PVH Europe’s consistent year-over-year growth.
Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing2.6.2020 15:00:00 CEST | Press release
Re-Vana Therapeutics Ltd, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, today announced that it has closed $3.25 million in pre-series A financing. The pre-series A round was oversubscribed by more than $1 million and closed in two tranches. The first tranche of $2.08 million was led by ExSight Ventures, with participation from InFocus Capital Partners and existing U.K. investors, including TechStart Ventures, Clarendon Fund Managers and Qubis Ltd. Visionary Ventures led the second closing round of $1.17 million, with additional investment from existing investors. With the second closing, Re-Vana became the first company in which all three specialized U.S. ophthalmic funds have invested in the same company. The proceeds will advance proof-of-concept development for Re-Vana’s proprietary photocrosslinked EyeLief™ and OcuLief™ biodegradable technologies for the delivery of biol